Home / Healthcare/ Bayer in frame to win first EU nod for high-precision cancer drug

Bayer in frame to win first EU nod for high-precision cancer drug


Comments / {{hitsCtrl.values.hits}} Views / Tuesday, 30 July 2019 00:10

Facebook

Reuters: Europe’s drug regulator has recommended approving Bayer’s Vitrakvi, putting the medicine on track to become the first in Europe to tackle tumours with a specific genetic mutation regardless of where in the body the disease started.

The drug is being recommended for adults and children with difficult to treat forms of cancer that are driven by a rare genetic mutation known as NTRK gene fusion, the European Medicines Agency (EMA) said on Friday (bit.ly/2Mi6s5o).

The European Commission has the final word on drug approvals but it generally follows EMA’s recommendation within a couple of months.

The EMA endorsement marks a boost for the German company’s drug development pipeline, which many analysts regard as too thin to make up for an expected decline in revenues from its two pharma bestsellers from about 2024.

The concept of a cancer drug’s use based on genetic growth drivers and not on the tumour’s location in the body received its first regulatory go-ahead in the US in 2017.

 


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Go digital now

Monday, 26 August 2019

It’s a no brainer. An agency head I know recently said to me: “The jury is still out on the impact of digital advertising on client business in Sri Lanka.” I said: “What makes you say that.” He was clear. He said: “No numbers to support i


No bourgeoisie, no democracy

Monday, 26 August 2019

In the dark, forbiddingly bleak topography of our dysfunctional democracy, the emergence of the National People Power (NPP) coalition is a refreshingly propitious development. The centre-left intelligentsia could not resist comparing it to the mass


STG who became SDG of the Central Bank

Monday, 26 August 2019

A hard taskmaster as Director of Economic Research When Dr. S.T.G. Fernando, fondly known as STG, was appointed as Director of Economic Research of the Central Bank in 1979, his fame – or perhaps, notoriety – as a hard taskmaster had travelled to


The Presidential Election: Into anarchy or out of anarchy?

Saturday, 24 August 2019

In politics there are no absolute truths, rights or wrongs: all is relative. Politics is about choices and alternatives. It is also the art of the possible. The best policy for the people is to work through the give


Columnists More

Special Report

SPECIAL REPORT MORE